港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物医药B类股

593.358

+15.4252.67%

涨家数：21

跌家数：7

平家数：6

市盈率：- -

高：598.497

开：578.227

低：578.109

收：577.933

成交量：4,027.04万

成交额：16.36亿

市值：3,788.68亿

流通市值：3,372.73亿

数据加载中...

总览新闻资讯

沛嘉医疗-B(09996.HK)：董事会董事长张一博士拟于公开市场继续增持股份

亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%

云顶新耀(01952)发布年度业绩收益17.07亿元同比大增141.51% 耐赋康®销售驱动强劲增长

智通财经网

东阿阿胶副总裁李庆川辞职；默克拟收购美国生物技术公司Terns | 医药早参

每日经济新闻

康宁杰瑞制药-B财年亏损1.139亿元人民币

康宁杰瑞制药-B(09966)发布年度业绩，年内亏损人民币1.14亿元同比盈转亏

同源康医药-B(02410)将于2026年AACR年会上展示五个创新药项目的研究成果

沛嘉医疗-B(09996)发布年度业绩收入同比增长15.82%至7.13亿元神经介入业务分部利润同比大幅增长86.6%

沛嘉医疗-B：2026年或成集团神经介入业务全球化扩张的起点

李氏大药厂(00950)：茵若飒取得国家药监局批准

复星医药2025年报：收入417亿，净利增速21.7%，创新药与境外收入占比同步提升

楚天科技：子公司楚天智能机器人目前专注于医药、医用、化妆品及技术同心圆等相关领域

兆科眼科-B(06622)公布2025年业绩税后亏损约2.09亿元同比收窄12%

Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income

归创通桥(02190)3月25日耗资约189.24万港元回购7.9万股

泰凌医药(01011)完成收购浙江康源医疗器械58.11%股权

执行董事龙振国增持德琪医药(06996)23.5万股每股作价约4.14港元

智通财经网

诺诚健华(09969)：练少娥获委任为公司秘书、授权代表

诺诚健华(09969)公布2025年业绩税后利润约6.44亿元同比扭亏为盈

新产业最新公告：获得超氧化物歧化酶测定试剂盒医疗器械注册证

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":593.3578,"timestamp":1774493003859,"preClose":577.93304,"halted":0,"volume":40270445,"delay":0,"changeRate":0.026689,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":15.424744,"latestTime":"03-26 10:43:25","open":578.2267,"high":598.49725,"low":578.109,"amount":1636220449,"amplitude":0.035278,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1774497600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"pbRate":5.179109,"peRate":-60.041027,"turnoverRate":0.001468,"increases":21,"decrements":7,"flats":5,"marketCap":378867596736,"floatMarketCap":337272776752},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":598.49725,"amplitude":0.035278,"preClose":577.93304,"low":578.109,"pbRate":"5.179109","latestPrice":593.3578,"volume":40270445,"delay":0,"open":578.2267,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":571.212,"twentyDayClose":537.703,"sixtyDayClose":574.89,"secType":"PLATE","market":"HK","turnoverRate":0.001468,"peRate":-60.041027,"marketCap":378867596736,"floatMarketCap":337272776752,"timestamp":1774493003859,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":21,"down":7,"flat":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622883271","title":"沛嘉医疗-B(09996.HK)：董事会董事长张一博士拟于公开市场继续增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883271","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883271?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 07:37","pubTimestamp":1774481825,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨沛嘉医疗-B(09996.HK)发布公告，董事会获悉，执行董事、首席执行官兼董事会董事长张一博士(“张博士”)透过其所控制的公司，自2026年3月26日起拟于公开市场上继续购买公司股份。是次持股增加合共代价预期不超过1500万港元。\r\n\r\n　　经张博士告知，持股增加反映其对公司内在价值的认可，以及其对公司发展前景及增长潜力的坚定信心。张博士将不排除根据适用法律及法规于适当时候进一步增加其于公司持股的可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260326/32098777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1100","BK1574","159891","BK1583","09996"],"gpt_icon":0},{"id":"2622588314","title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622588314","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622588314?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 07:28","pubTimestamp":1774481290,"startTime":"0","endTime":"0","summary":"3月26日，头部创新药企业亚盛医药发布2025年全年业绩。作为公司首款商业化产品，耐立克在2025年迎来医保落地后的首个完整销售年份，销售额实现显著增长，达到4.35亿元人民币，同比大幅增长81%。公司第二款产品、中国首个上市的国产原创Bcl-2抑制剂利生妥自2025年7月获批后快速放量，截至报告期末的5个月内实现销售额7058万元人民币。业绩增长由已上市的两大核心产品“双引擎”高效驱动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1574","BK4139","06855","BK1161"],"gpt_icon":0},{"id":"2622883992","title":"云顶新耀(01952)发布年度业绩 收益17.07亿元 同比大增141.51% 耐赋康®销售驱动强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883992","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883992?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 07:23","pubTimestamp":1774481019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布截至2025年12月31日止年度业绩，集团收益人民币17.07亿元，同比增长141.51%;股东应占亏损2.98亿元;研发开支5.11亿元;毛利11.82亿元，同比增长124.32%。收益增加主要由于耐赋康在已商业化市场的销售额继续上升所致。在中国市场，将耐赋康纳入国家医保药品目录为关键的增长动力，以致截至2025年12月31日止年度的耐赋康收益大幅增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"云顶新耀(01952)发布年度业绩 收益17.07亿元 同比大增141.51% 耐赋康®销售驱动强劲增长","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2622883390","title":"东阿阿胶副总裁李庆川辞职；默克拟收购美国生物技术公司Terns | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883390","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883390?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 07:06","pubTimestamp":1774479983,"startTime":"0","endTime":"0","summary":"丨2026年3月26日星期四丨NO.1东阿阿胶副总裁李庆川辞职3月25日，东阿阿胶发布公告，称董事会近日收到李庆川提交的书面辞职报告，由于工作变动原因，李庆川申请辞去公司副总裁职务。辞职后，李庆川将担任公司党委副书记职务。截至公告日，李庆川持有公司20639股限制性股票，原定任期届满之日为2027年8月6日。点评：公司表示该项辞职不会影响公司相关工作的正常进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263684586713.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263684586713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0070302665.USD","LU2361044865.SGD","LU1291159041.SGD","LU1116320737.USD","SG9999014559.SGD","SG9999002232.USD","LU2089984988.USD","LU2468319806.SGD","MRK","BK4588","LU0006306889.USD","BK4585","LU2125154778.USD","BK4516","688197","LU2324357040.USD","SG9999002224.SGD","BK1574","IE00B1BXHZ80.USD","LU0861579265.USD","BK0183","SG9999001440.SGD","SG9999014575.USD","LU0985320562.USD","LU2106854487.HKD","LU1934455863.HKD","BK4550","IE00BN8TJ469.HKD","LU0203347892.USD","IE0009355771.USD","LU1929549753.HKD","BK1161","BK0028","IE00BLSP4239.USD","LU2361045086.USD","LU1201861249.SGD","LU0130102774.USD","LU0965509283.SGD","LU2023250504.SGD","LU0965509101.SGD","BK0188","LU1023059063.AUD","LU2023250843.SGD","LU0868494708.USD","LU0289739699.SGD","LU0942090050.USD","LU0477156953.USD","LU0266013472.USD","000423","LU1699723380.USD","LU1066051498.USD","IE0002141913.USD","LU0058720904.USD","IE00B4R5TH58.HKD","IE00BBT3K403.USD","LU1162221912.USD","BK4533","LU1989772923.USD","LU0648001328.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","SG9999013999.USD","LU0965508806.USD","LU2361044949.HKD","LU0320765489.SGD","LU0868494617.USD","LU0965509010.AUD","LU1093756168.USD","LU1037948897.HKD","LU0106261372.USD","SG9999014567.USD","SG9999001176.SGD","IE00BLSP4452.SGD","BK4534","LU1430594728.SGD","LU0211331839.USD","BK4559","LU2461242641.AUD","SG9999014542.SGD","LU1116320901.HKD","LU0203345920.USD","BK1515","LU1934455194.USD","LU1934455277.USD","LU2360032135.SGD","BK0175","LU0208291251.USD","IE00BSNM7G36.USD","SGXZ57979304.SGD","LU1066051811.HKD","SG9999001176.USD","LU0265550359.USD","BK0187","LU1066053197.SGD","LU1974910355.USD","LU0234572021.USD","LU0238689110.USD","BK0239","LU1057294990.SGD","LU0432979614.USD","LU1061106388.HKD","LU2112291526.USD","LU0122379950.USD","LU1571399168.USD","LU1585245621.USD","LU1035773651.USD","LU2125154935.USD","600812","SG9999014674.SGD","SG9999015341.SGD","BK4007","LU1917777945.USD","IE00BJJMRZ35.SGD","LU0265550946.USD","LU1069347547.HKD","IE00B2B36J28.USD","09939","LU1941712264.USD","LU0098860793.USD","LU1037948541.HKD","LU0320765646.SGD","LU1989772840.SGD","LU1989771016.USD","LU0130517989.USD","LU1066051225.USD","LU0980610538.SGD","BK0196","LU1093756325.SGD","SG9999015358.SGD","BK0010","IE00BJT1NW94.SGD","IE000M9KFDE8.USD","LU1941712348.USD"],"gpt_icon":0},{"id":"1153293212","title":"康宁杰瑞制药-B财年亏损1.139亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1153293212","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153293212?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 23:41","pubTimestamp":1774453268,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（9966.HK）公布最新财年业绩，录得净亏损达1.139亿元人民币。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2622841070","title":"康宁杰瑞制药-B(09966)发布年度业绩，年内亏损人民币1.14亿元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841070","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622841070?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 23:14","pubTimestamp":1774451655,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布截至2025年12月31日止年度业绩，该公司取得收入人民币5.66亿元，同比减少11.54%;年内亏损人民币1.14亿元，同比盈转亏;每股亏损人民币0.12元。公告称，研发开支由截至2024年12月31日止年度的人民币4.04亿元增加至截至2025年12月31日止年度的人民币5.72亿元，主要由于(i)正在进行的临床试验数目增加;(ii)公司临床研究规模的扩大;及(iii)公司候选药物的临床试验进展。下表列载于所示年度按性质划分的研发开支明细。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK1574","UCmain","MCNHmain","CNHmain","CYB","MUCmain","BK1161"],"gpt_icon":0},{"id":"2622072086","title":"同源康医药-B(02410)将于2026年AACR年会上展示五个创新药项目的研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072086","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072086?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 22:42","pubTimestamp":1774449755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司将于2026年美国癌症研究协会(AACR)年会壁报环节展示TY-0609(CDK4抑制剂)、TY-2699a(CDK7抑制剂 )、 TY-2719(EGFR/FAK(PROTAC)抑制剂)、PI3Kα(PI3Kα抑制剂)、TY-1054 (YAP-TEAD抑制剂)五个在研创新药项目的研究进展和成果，此次展示的五个项目均为本公司自主研发的抗肿瘤小分子创新候选药物。本届AACR年会将于2026 年4月17日至22日在美国圣地亚哥举行，本公司参会壁报将分别于4月19日至4月 21日展示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","BK1574","159992","06978","02410","BK1161","159938"],"gpt_icon":0},{"id":"2622072988","title":"沛嘉医疗-B(09996)发布年度业绩 收入同比增长15.82%至7.13亿元 神经介入业务分部利润同比大幅增长86.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072988","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072988?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 22:23","pubTimestamp":1774448601,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B 发布截至2025年12月31日止年度业绩，该集团取得收入7.13亿元，同比增长15.82%;股东应占亏损同比收窄10.28%;每股基本亏损0.31元。报告期内，集团实现收入人民币7.13亿元，同比增长15.82%。神经介入业务分部利润同比增长86.6%至人民币9720万元，而经导管瓣膜治疗业务分部亏损同比收窄20.2%至人民币2.16亿元。若剔除前沿技术业务组成实体应占的亏损，集团年度经调整亏损将为人民币1.11亿元，同比收窄44.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","159891","BK1100","09996"],"gpt_icon":0},{"id":"1194672043","title":"沛嘉医疗-B：2026年或成集团神经介入业务全球化扩张的起点","url":"https://stock-news.laohu8.com/highlight/detail?id=1194672043","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194672043?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 22:15","pubTimestamp":1774448130,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B预计，2026年将成为集团在神经介入业务领域迈向全球市场布局的初步阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1583","BK1574","09996"],"gpt_icon":0},{"id":"2622071591","title":"李氏大药厂(00950)：茵若飒取得国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071591","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622071591?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 21:37","pubTimestamp":1774445826,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，于2026年3月17日，中国国家药品监督管理局(国家药监局)已批准茵若飒(由Cosette Pharmaceuticals拥有并已授予李氏大药厂许可)用于治疗具有中重度症状(不包括泌尿系症状)的绝经后女性外阴阴道萎缩。继本公司全资附属公司兆科药业(合肥)有限公司进行的第III期、多中心、随机、双盲、平行对照临床试验成功完成后，是次获批标志着一个重要的里程碑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06622","BK1574","BK1191","BK1587","BK1583","00950"],"gpt_icon":0},{"id":"2622074818","title":"复星医药2025年报：收入417亿，净利增速21.7%，创新药与境外收入占比同步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074818","media":"IPO早知道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074818?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 21:32","pubTimestamp":1774445520,"startTime":"0","endTime":"0","summary":"报告期内，经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，增长主要系对外授权收入增加所致。创新药管线：研发投入转向商业兑现的效率提升复星医药2025年研发总投入达59.13亿元，同比增长6.46%，其中创新药品相关研发投入43.03亿元，同比大增15.98%，占研发总投入的72.77%，占比同比提升5.97个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-25/doc-inhsfmmn0790711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK0183","BK0028","BK0096","BK0175","02196","BK1515","BK1161","BK0196","600196","BK0012","BK1574","BK1191","BK0239","BK0187","BK0060","159992","BK1593","BK0188"],"gpt_icon":0},{"id":"2622074580","title":"楚天科技：子公司楚天智能机器人目前专注于医药、医用、化妆品及技术同心圆等相关领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074580","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074580?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 21:31","pubTimestamp":1774445460,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月25日，楚天科技在互动平台回答投资者提问时表示，公司专注于为全球医药客户提供自动化、智能化整体解决方案，相关业务及技术拓展围绕着技术同心圆、客户同心圆和产品同心圆展开。子公司楚天智能机器人目前同样专注于医药、医用、化妆品及技术同心圆等相关领域，工业机器人系用于公司产品中，提升产品整体性能。目前占公司业务占比较小，请投资者注意投资风险。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-25/doc-inhsfmmn0792719.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-25/doc-inhsfmmn0792719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK0061","BK1515","300358","ROBO","BK0028","BK1161","159938","BK0251","BK1574","BK0077"],"gpt_icon":0},{"id":"2622078438","title":"兆科眼科-B(06622)公布2025年业绩 税后亏损约2.09亿元 同比收窄12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078438","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078438?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:46","pubTimestamp":1774439191,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B(06622)公布2025年业绩，收益3197.4万元，同比减少53.88%;税后亏损约2.09亿元，同比收窄12%。公告称，亏损减少主要源于集团继续严格控制行政费用及销售及分销开支，反映年内成本控制有所加强及营运架构效率提升。此外，研发开支随着若干主要开发里程碑达成而有所减少，并无如上一年度产生非经常性开支亦进一步推动改善。尽管并无如上一年度取得一次性的许可收入，且2025年利率下调令银行利息收入减少，惟集团取得的年内亏损仍然实质收窄。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","BK1191","06622","BK1587"],"gpt_icon":0},{"id":"2622078184","title":"Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078184","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078184?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:43","pubTimestamp":1774439016,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.In China, 国家药监局 accepted the biological products license application for 贝伐单抗玻璃体腔内注射液 , supporting a potential first-mover position in a wAMD-focused bevacizumab filing.In the US, FDA approved the new drug investigational application for 环孢素眼用凝胶 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL94t3zx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","06622","BK1583","BK1587"],"gpt_icon":0},{"id":"2622078523","title":"归创通桥(02190)3月25日耗资约189.24万港元回购7.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078523","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078523?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:34","pubTimestamp":1774438449,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)公布，2026年3月25日耗资约189.24万港元回购7.9万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02190","BK1100","BK1587","BK1574"],"gpt_icon":0},{"id":"2622002020","title":"泰凌医药(01011)完成收购浙江康源医疗器械58.11%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2622002020","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622002020?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:21","pubTimestamp":1774437695,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药 发布公告，就有关公司拟约1.16亿元收购浙江康源医疗器械58.11%股权的相关事宜。公司已于2026年3月25日按每股代价股份0.45港元的发行价向8名卖方发行及配发2.75亿股新股份以完成支付代价，通函“先决条件”分节所载买卖协议及补充协议的所有先决条件已获达成。收购事项完成后，公司透过全资附属公司间接持有浙江康源医疗器械有限公司58.11%股权，其财务业绩将于集团账目内综合入账。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK1100","01011","09996","BK1574","09997","BK1222","BK1583","BK1191"],"gpt_icon":0},{"id":"2622020093","title":"执行董事龙振国增持德琪医药(06996)23.5万股 每股作价约4.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622020093","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622020093?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:14","pubTimestamp":1774437259,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，3月24日，执行董事龙振国增持德琪医药(06996)23.5万股，每股作价4.136港元，总金额约为97.2万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260325/20260325191438_18992.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260325/20260325191438_18992.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"执行董事龙振国增持德琪医药(06996)23.5万股 每股作价约4.14港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1191","06996","BK1583"],"gpt_icon":0},{"id":"2622205220","title":"诺诚健华(09969)：练少娥获委任为公司秘书、授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2622205220","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622205220?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:08","pubTimestamp":1774436925,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，李谢佩珊女士已提请辞任公司的公司秘书，并就香港联合交易所有限公司证券上市规则第3.05条而言，不再担任公司的授权代表;及根据公司条例(香港法例第622章)第16部规定，不再担任公司于香港接收送达法律程序文件及通知的法定代表(法律程序代理人)，自2026年3月25日起生效。此外，练少娥女士已获委任为公司秘书、授权代表及法律程序代理人，自2026年3月25日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","09969","688428","BK0239"],"gpt_icon":0},{"id":"2622302709","title":"诺诚健华(09969)公布2025年业绩 税后利润约6.44亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2622302709","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622302709?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436401,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 公布2025年业绩，收益约23.75亿元，同比增长135.27%;税后利润约6.44亿元，同比扭亏为盈;经调整利润约6.75亿元，同比扭亏为盈。公告称，收益增长主要是由于药物销售的强劲增长，以及与Zenas Biopharma及Prolium合作所产生的许可收益。药物收益同比增加43.4%至14.424亿元，是由于奥布替尼持续的高增长，以及坦昔妥单抗于2025年第四季度上市。公司首次实现扭亏为盈，达成重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","688428","09969","BK0239"],"gpt_icon":0},{"id":"2622027325","title":"新产业最新公告：获得超氧化物歧化酶测定试剂盒医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027325","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027325?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 18:33","pubTimestamp":1774434786,"startTime":"0","endTime":"0","summary":"新产业(300832.SZ)公告称，公司近日收到广东省药监局颁发的1项Ⅱ类《医疗器械注册证》，产品为超氧化物歧化酶测定试剂盒(邻苯三酚底物法)，有效期至2031年3月23日，用于体外定量测定人血清或血浆中超氧化物歧化酶活性，临床上辅助诊断机体抗氧化能力。该产品丰富了公司生化检测“肾功能”项目类别，对公司发展具有正面影响，但对近期生产经营和业绩无重大影响。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260325/32098010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1222","159883","BK1100","BK1583","09996","BK1574","09997","BK0239","300832"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":1,"totalSize":292,"code":"91000000","status":"200"}]}}